Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

<p>Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>

Gardado en:
Detalles Bibliográficos
Autor Principal: Seyed Reza Mousavi (13223324) (author)
Outros autores: Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author)
Publicado: 2025
Subjects:
Medicine
Cell Biology
Neuroscience
Physiology
Pharmacology
Biotechnology
Immunology
Science Policy
Mental Health
patients received either
day monitoring period
total antivenom consumption
treating snakebite envenomation
antivenom units administered
razi antivenom group
snakebite envenomation
razi antivenom
razi group
antivenom infusion
49 units
40 units
snafab antivenom
razi antivenoms
snafab group
serum sickness
recovery rate
primary endpoint
muscle weakness
mean number
may 15th
april 17th
anaphylactic shock
adverse events
98 %).
92 ).
27 ).
100 percent
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares

Títulos similares